Staccato alprazolam

DRUG5 trials

Sponsors

Engage Therapeutics, Inc., UCB Biopharma SRL

Conditions

EpilepsyHealthy ParticipantsStereotypical Prolonged Seizures

Phase 1

A Relative Bioavailability Study of Staccato Alprazolam Versus Oral Alprazolam in Healthy Study Participants

CompletedNCT05626439

UCB Biopharma SRLHealthy Participants

Start: 2022-12-28End: 2023-02-24Updated: 2024-03-18

A Study to Assess the Time to Onset of Action of Staccato Alprazolam Versus Midazolam and Diazepam in Healthy Participants

CompletedNCT07020988

UCB Biopharma SRLHealthy Participants

Start: 2025-06-12End: 2026-01-21Updated: 2026-02-20

Phase 2

Inpatient, Dose-Ranging Study of Staccato Alprazolam in Epilepsy With Predictable Seizure Pattern

CompletedNCT03478982

Engage Therapeutics, Inc.Epilepsy

Start: 2018-03-16End: 2020-01-04Updated: 2021-02-03

Phase 3

A Study to Test the Safety and Tolerability of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures

Enrolling by invitationNCT05076617

UCB Biopharma SRLStereotypical Prolonged Seizures

Start: 2022-02-03End: 2028-11-30Target: 300Updated: 2026-03-27

A Study to Test the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures

RecruitingNCT05077904

UCB Biopharma SRLStereotypical Prolonged Seizures

Start: 2021-12-07End: 2026-04-01Target: 350Updated: 2026-04-02

Related Papers

A randomized phase 2b efficacy study in patients with seizure episodes with a predictable pattern using Staccato® alprazolam for rapid seizure termination

Epilepsia2022-10-2122 citations